A multi-methods study of the factors influencing the adoption of proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors
(2021)
Thesis
Odingo, M. O. (2021). A multi-methods study of the factors influencing the adoption of proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors. (Thesis). Keele University
Introduction A new class of lipid lowering agent Proprotein Convertase Subtilisin/Kexin Type 9 inhibitors (PCSK9) was launched in 2015 for the treatment of heterozygous familial hypercholesterolemia (HeFH) in combination with statin therapy. There a... Read More about A multi-methods study of the factors influencing the adoption of proprotein convertase subtilisin/kexin-type 9 (PCSK9) inhibitors.